Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Juno ROCKETs On Fast Clinical Hold Resolution

Executive Summary

The FDA lifted a clinical hold on the Phase II ROCKET clinical trial for Juno's lead CAR-T therapy candidate JCAR015 less than a week after it was instituted, allowing the company to proceed without using fludarabine in a pre-conditioning chemotherapy regimen.

You may also be interested in...



Juno Stresses Differences Between Its CAR-Ts As JCAR015 Trial Put On Hold Again

Juno stressed structural differences, safety record and potential of its JCAR017 CAR-T therapy during a Nov. 23 call about the disappointing hold on its ROCKET ALL study for JCAR015 – the second clinical hold for the company’s most advanced development program.

Synthetic Biology And The Computerization Of Drug Development

Synthetic biology offers opportunity across many industries, but the ultimate prize may be health care. The millions of dollars investors have poured into companies developing CAR-T cell therapies and gene editing technologies points to growing confidence in the power of gene manipulation to generate novel, approvable therapeutics, even if for now these are just the early steps toward creating fully synthetic organisms.

New Interim CAR-T Data Support Kite’s BLA Submission Plans

Kite Pharma Inc. executives reiterated plans on Sept. 26 to pursue US FDA approval this year for the chimeric antigen receptor T cell (CAR-T) therapy known as KTE-C19, keeping the company on track to seek accelerated approval for a form of advanced lymphoma before any of its competitors.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC096877

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel